AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

The Use of Pentraxin as a Molecular Marker for Oocyte Quality

Technology Benefits
• No risk to the embryo • Optimizes chances of successful pregnancy • Avoids potential for physically difficult and financially difficult high-order multiple births
Detailed Technology Description
Novel biomarker for determining oocyte ability to fertilize in vitro and implant after transfer into uterus#OB #healthcare #diagnostictool #diagnostics #detection
*Abstract

One of the main challenges in utilizing Assisted Reproductive Technologies (ART) is the informed selection of embryos for transfer. Northwestern investigators have demonstrated that the relative abundance of mRNA coding for Pentraxin-3 in cumulus cells surrounding the oocyte correlates with the ability of oocytes to fertilize in vitro and to implant following placement of the embryo in the uterus. Pentraxin-3 is a protein initially studied for its role in inflammatory reactions. The discovery of its correlation with viability can be exploited by physicians and fertility clinics performing Assisted Reproductive Technologies (ART) as an assay for fertility and for predicting the developmental potential of the human embryo without risking damage or destruction of the embryo. The metric can also be used as a guide for selecting in vitro- produced embryos for transfer so that only embryos with the best developmental potential will be selected for placement in the uterus to establish pregnancy. The main benefit of selecting embryos with the best potential is the ability to transfer fewer embryos and minimize the chances of high-order multiple births, which can cause considerable physical and emotional stress

*Inventors
Xingqi (John) ZhangRalph R. KazerEdmond Confino
Country/Region
USA

For more information, please click Here
Mobile Device